The AGE-breaker ALT-711

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • liftsiron
    Administrator
    • Nov 2003
    • 18434

    The AGE-breaker ALT-711

    NCBI Logo
    Skip to main content
    Skip to navigation
    Resources
    How To
    About NCBI Accesskeys

    Sign in to NCBI
    PubMed
    US National Library of Medicine National Institutes of Health



    Diabetes. 2012 Jun;61(6):1562-72. doi: 10.2337/db11-0750. Epub 2012 Mar 13.
    The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes.
    Freidja ML1, Tarhouni K, Toutain B, Fassot C, Loufrani L, Henrion D.
    Author information
    Abstract

    Flow-mediated remodeling of resistance arteries is essential for revascularization in ischemic diseases, but this is impaired in diabetes. We hypothesized that breaking advanced glycation end product (AGE) cross-links could improve remodeling in mesenteric resistance arteries in Zucker diabetic fatty (ZDF) rats compared with lean Zucker (LZ) rats. Arteries, exposed to high (HF) or normal (NF) blood flow after alternate arterial ligation in vivo, were collected after 2 weeks. In LZ rats, HF artery diameter was larger than for NF vessels, but this was not the case in ZDF rats. Endothelium-mediated dilation in ZDF rats, which was lower than in LZ rats, was further decreased in HF arteries. Treatment of rats with the AGE-breaker 4,5-dimethyl-3-phenacylthiazolium chloride (ALT-711) (3 mg/kg/day; 3 weeks) reversed diabetes-induced impairment of HF-dependent remodeling. ALT-711 also improved endothelium nitric oxide-dependent relaxation in mesenteric resistance arteries. Reactive oxygen species reduction restored relaxation in ZDF rats but not in LZ or ALT-711-treated rats. AGEs were reduced in ALT-711-treated ZDF rats compared with ZDF rats. Metalloproteinase activity, necessary for HF-dependent remodeling, was reduced in ZDF rats compared with LZ rats and restored by ALT-711. Thus, targeting AGE cross-links may provide a therapeutic potential for overcoming microvascular complications in ischemic disorders occurring in diabetes.
    ADMIN/OWNER@Peak-Muscle
Working...